Company Profile

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The Company products include XYOSTED (testosterone enanthate) injection, NOCDURNA (desmopressin acetate), OTREXUP (methotrexate) injection, Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector and Teriparatide Injection. Its testosterone enanthate injection product is indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Its desmopressin acetate is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate.

Employees

202

Sector

Medical Equipment, Supplies & Distribution

More about the company

22-05-24	Antares Pharma, Inc. Announces Management Changes	CI
22-05-24	Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from NASDAQ Composite Index	CI
22-05-24	Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P Pharmaceuticals Select Industry Index	CI
22-05-24	Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P Global BMI Index	CI
22-05-24	Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P TMI Index	CI
22-05-22	Halozyme Therapeutics, Inc. completed the acquisition of Antares Pharma, Inc..	CI
22-05-12	Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition	MT
22-05-10	Antares Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-04-26	Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares	MT
22-04-14	Ladenburg Thalmann Downgrades Antares Pharma to Neutral From Buy	MT
22-04-14	HC Wainwright Downgrades Antares Pharma to Neutral From Buy; Price Target is $5.60	MT
22-04-14	Piper Sandler Downgrades Antares Pharma to Neutral From Overweight, Adjusts Price Target to $5.60 From $6	MT
22-04-14	Raymond James Downgrades Antares Pharma to Market Perform From Strong Buy	MT

22-04-14	Ladenburg Thalmann Downgrades Antares Pharma to Neutral From Buy	MT
22-04-14	HC Wainwright Downgrades Antares Pharma to Neutral From Buy; Price Target is $5.60	MT
22-04-14	Piper Sandler Downgrades Antares Pharma to Neutral From Overweight, Adjusts Price Target to $5.60 From $6	MT
22-04-14	Raymond James Downgrades Antares Pharma to Market Perform From Strong Buy	MT
22-04-13	Truist Securities Downgrades Antares Pharma to Hold From Buy, Adjusts PT to $5.60 From $7.00	MT

22-05-26	Antares Pharma : Statement of Changes in Beneficial Ownership (Form 4)	PU
22-05-26	Antares Pharma : Statement of Changes in Beneficial Ownership (Form 4)	PU
22-05-26	Antares Pharma : Statement of Changes in Beneficial Ownership (Form 4)	PU
22-05-26	Antares Pharma : Statement of Changes in Beneficial Ownership (Form 4)	PU
22-05-26	Antares Pharma : Statement of Changes in Beneficial Ownership (Form 4)	PU

Director	Title	Age	Since
Helen Torley BRD	Director/Board Member	63	2022-05-23
Nicole LaBrosse BRD	Director/Board Member	43	2022-05-23
Thomas Bergmann BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ANTARES PHARMA, INC.	-.--%	+0.18%	-	-	955M
ABBOTT LABORATORIES	+0.84%	-0.28%	-20.64%	-2.32%	175B
MEDTRONIC PLC	+0.61%	+2.42%	+5.10%	+9.67%	113B
CENCORA, INC.	+0.04%	-0.72%	+12.06%	+90.61%	62.08B
HOYA CORPORATION	+0.79%	+5.15%	+97.32%	+105.16%	61.26B
BECTON, DICKINSON AND COMPANY	+0.30%	+0.46%	-24.32%	-39.07%	44.26B
MEDLINE INC.	+1.18%	+10.75%	-	-	38.33B
DEXCOM, INC.	-0.12%	-0.03%	-6.38%	-45.47%	24.29B
STERIS PLC	-0.11%	+2.25%	+0.06%	+20.17%	22.05B
TERUMO CORPORATION	+1.01%	-1.37%	-19.50%	+13.06%	19.71B
Average	+0.44%	+1.18%	+5.46%	+18.98%	62.26B
Weighted average by Cap.	+0.58%	+0.75%	+3.93%	+20.35%

Antares Pharma, Inc. Stock

Equities

ATRS

US0366421065

Medical Equipment, Supplies & Distribution

Latest news: Antares Pharma, Inc.

Analysts' recommendations: Antares Pharma, Inc.

Press Releases: Antares Pharma, Inc.

News in other languages: Antares Pharma, Inc.

Managers and Directors: Antares Pharma, Inc.

Other Medical Equipment, Supplies & Distribution

Company Profile